

FILED
U.S. DISTRICT COURT
DISTRICT OF MARYLAND
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MARYLAND
2008 MAY -8 P 2:20

FILED
U.S. DISTRICT COURT
DISTRICT OF MARYLAND

2008 MAY -5 P 3:19

CLERK'S OFFICE
27 BALTIMORE

UNITED STATES OF AMERICA,)
)
Plaintiff,)
)
v.)
)
SCIENTIFIC LABORATORIES, INC.,)
a corporation, and)
RAJESHWARI PATEL, and)
AMIT ROY,)
individuals)
)
Defendants.)

Civil Action No. _____

CONSENT DECREE OF
PERMANENT INJUNCTION

FILED
U.S. DISTRICT COURT
DISTRICT OF MARYLAND
2008 MAY 11 11:58

Plaintiff, the United States of America, by its undersigned attorneys, having filed a complaint for permanent injunction against Scientific Laboratories, Inc. ("SLI"), a corporation, and Rajeshwari Patel and Amit Roy, individuals (collectively, "Defendants"), and Defendants, without admitting or denying the allegations in the Complaint, having appeared and having consented to entry of this Decree without contest and before any testimony has been taken, and the United States of America, having consented to this Decree;

IT IS HEREBY ORDERED, ADJUDGED, AND DECREED as follows:

1. This Court has jurisdiction over the subject matter of this action and has personal jurisdiction over all parties to this action.
2. The Complaint for Permanent Injunction states a cause of action against Defendants under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-397 (the "Act").
3. The Complaint alleges that Defendants violate the Act, 21 U.S.C. § 331(a), by introducing and causing to be introduced, and delivering and causing to be delivered for introduction, into interstate commerce articles of drug, as defined by 21 U.S.C. § 321(g)(1), that

are adulterated within the meaning of 21 U.S.C. § 351(a)(2)(B), in that the drugs have been manufactured, processed, packed, labeled, held, and distributed in violation of current good manufacturing practice ("CGMP"), 21 C.F.R. Parts 210 and 211.

4. The Complaint alleges that Defendants violate the Act, 21 U.S.C. § 331(k), by causing the adulteration within the meaning of 21 U.S.C. § 351(a)(2)(B) of articles of drug after shipment of one or more of their components in interstate commerce.

5. The Complaint alleges that Defendants violate the Act, 21 U.S.C. § 331(a), by introducing and causing to be introduced, and delivering and causing to be delivered for introduction, into interstate commerce articles of drug that are misbranded under 21 U.S.C. § 352(f)(1), in that their labeling fails to bear adequate directions for use.

6. The Complaint alleges that Defendants violate the Act, 21 U.S.C. § 331(k), by causing drugs that Defendants hold for sale after shipment of one or more of their components in interstate commerce to become misbranded within the meaning of U.S.C. § 352(f)(1).

7. The Complaint alleges that Defendants violate the Act, 21 U.S.C. § 331(d), by introducing and causing to be introduced, and delivering and causing to be delivered for introduction, into interstate commerce new drugs, as defined by 21 U.S.C. § 321(p), that are neither approved pursuant to 21 U.S.C. § 355(a), nor exempt from approval pursuant to 21 U.S.C. § 355(i).

8. Upon entry of this Decree, Defendants and each and all of their directors, officers, agents, representatives, employees, attorneys, successors, and assigns, and any and all persons in active concert or participation with any of them who receive actual notice of this Decree by personal service or otherwise, are permanently restrained and enjoined under 21 U.S.C. § 332(a) from directly or indirectly manufacturing, processing, packing, labeling, holding, or distributing any

articles of drug unless and until:

A. Defendants' methods, facilities, and controls used to manufacture, process, pack, label, hold, and distribute drugs are established, operated, and administered in compliance with current good manufacturing practice ("CGMP"). See 21 C.F.R. Parts 210 and 211;

B. Defendants retain, at Defendants' expense, an independent person or persons (the "CGMP expert"), to make inspections of their drug manufacturing facilities to determine whether the methods, facilities, and controls are operated and administered in conformity with CGMP. The CGMP expert shall be qualified by education, training, and experience to conduct such inspections, and shall be without personal or financial ties (other than the consulting agreement between the parties) to Defendants or their immediate families. Defendants shall notify FDA in writing of the identity of the CGMP expert as soon as they retain such expert. The CGMP expert shall:

(i) perform a comprehensive inspection of Defendants' facilities and the methods and controls used to manufacture, process, pack, label, hold, and distribute drugs to determine whether they are in compliance with CGMP;

(ii) when appropriate, certify in writing to FDA the Defendants' facilities, methods, and controls are in compliance with CGMP; and

(iii) submit to FDA as part of the certification a full and complete written report prepared by the CGMP expert of the results of his or her inspection;

C. Defendants cease manufacturing, processing, packing, labeling, holding, and distributing B-Vex Suspension, Ben-Tann Suspension, D-Tann Suspension, D-Tann AT Suspension, D-Tann CT Suspension, D-Tann DM Suspension, D-Tann HC Suspension, Dur-Tann DM Suspension, Duratan DM Suspension, L-All 12 Suspension, Nazarin Liquid, and Nazarin

HC Liquid and any other new drug, as defined in 21 U.S.C. § 321(p), that lacks an approved new drug application or approved abbreviated new drug application under 21 U.S.C.

§ 355, unless the drug is exempt from the approval requirements pursuant to an effective exemption under 21 U.S.C. § 355(i), or unless the drug is made and labeled in strict conformity with all of the requirements set forth in any of the OTC drug monographs, 21 C.F.R. Part 330;

D. Defendants cease manufacturing, processing, packing, labeling, holding, and distributing all drugs that are misbranded under 21 U.S.C. § 352(f)(1);

E. Defendants report to FDA in writing the actions they have taken to:

(1) correct the CGMP deviations brought to Defendants' attention by FDA, the CGMP expert, and/or that are otherwise within Defendants' knowledge;

(2) ensure that the methods used in, and the facilities and controls used for, manufacturing, processing, packing, labeling, holding, and distributing drugs are operated and will be continuously administered in conformity with CGMP;

(3) ensure that their new drugs are the subject of approved new drug applications or approved abbreviated new drug applications under 21 U.S.C. § 355, or are exempt from the approval requirements pursuant to an effective exemption under 21 U.S.C. § 355(i), or are made and labeled in strict conformity with all of the requirements set forth in any of the OTC drug monographs, 21 C.F.R. Part 330; and

(4) ensure their products have adequate directions for use;

F. Defendants recall any unapproved new drug that they have manufactured, processed, packed, labeled, held, or distributed on or after January 1, 2007, and destroy the drugs in accordance with the procedures provided in paragraph 10;

G. FDA representatives inspect Defendants' facilities to determine whether the

requirements of this Decree have been met, and whether Defendants' facilities are operating in conformity with CGMP, the Act, and its implementing regulations. FDA's inspection will commence within forty-five (45) calendar days of FDA's receipt of Defendants' report under subparagraph 8(E); and

H. FDA notifies Defendants in writing that Defendants appear to be in compliance with the requirements set forth in subparagraphs 8(A)-(G). FDA will notify Defendants whether they appear to be in compliance within forty-five (45) days following the conclusion of the inspection under subparagraph 8(G). In no circumstance will FDA's silence be construed as a substitute for written notification.

I. Notwithstanding the foregoing provisions of paragraph 8, Defendants may manufacture, process, pack, and hold such quantities of drugs as are necessary for the purpose of preparing or supporting a new drug or investigational new drug application, but such drugs may not be distributed under any circumstances without prior written authorization from FDA.

9. Upon entry of this Decree, Defendants and each and all of their directors, officers, agents, employees, representatives, successors, assigns, attorneys, and any and all persons in active concert or participation with any of them, who have received actual notice of this Decree by personal service or otherwise, are permanently restrained and enjoined under 21 U.S.C. § 332(a) from directly or indirectly doing or causing to be done any act that:

A. Violates 21 U.S.C. § 331(a), by introducing or delivering, or causing to be introduced or delivered, into interstate commerce drugs within the meaning of 21 U.S.C. § 321(g)(1) that are adulterated within the meaning of 21 U.S.C. § 351(a)(2)(B);

B. Violates 21 U.S.C. § 331(k), by causing drugs within the meaning of 21 U.S.C. § 321(g)(l) that Defendants hold for sale after shipment of one or more of their components in interstate commerce to become adulterated within the meaning of 21 U.S.C. § 351(a)(2)(B);

C. Violates 21 U.S.C. § 331(d), by introducing or delivering, or causing to be introduced or delivered, into interstate commerce new drugs within the meaning of 21 U.S.C. § 321(p) that are neither approved pursuant to 21 U.S.C. § 355, nor exempt from approval pursuant to 21 U.S.C. § 355(i);

D. Violates 21 U.S.C. § 331(a), by introducing or delivering, or causing to be introduced or delivered, into interstate commerce drugs within the meaning of 21 U.S.C. § 321(g)(l) that are misbranded within the meaning of 21 U.S.C. § 352(f)(1); and

E. Violates 21 U.S.C. § 331(k), by causing drugs within the meaning of 21 U.S.C. § 321(g)(1) that Defendants hold for sale after shipment of one or more of their components in interstate commerce to become misbranded within the meaning of 21 U.S.C. §§ 352(f)(1).

10. Within fifteen (15) calendar days of entry of this Decree, Defendants shall, under FDA supervision, destroy: (a) all of B-Vex Suspension, Ben-Tann Suspension, D-Tann Suspension, D-Tann AT Suspension, D-Tann CT Suspension, D-Tann DM Suspension, D-Tann HC Suspension, Dur-Tann DM Suspension, Duratan DM Suspension L-All 12 Suspension, Nazarin Liquid, and Nazarin HC Liquid, and any other new drug within the meaning of 21

U.S.C. § 321(p), in Defendants' possession, custody, and/or control; (b) all other drugs in Defendants' possession, custody, and/or control that are also adulterated because they were not manufactured, processed, packed, labeled, held, and/or distributed in accordance with CGMP; and (c) all other drugs in Defendants' possession, custody, and/or control that are misbranded. All costs of destruction shall be borne by Defendants. Defendants shall reimburse FDA for the supervision of the destruction at the rates set forth in paragraph 15 of this Decree. Defendants shall not dispose of any drugs in a manner contrary to any federal, state, or local laws, including but not limited to, the National Environmental Policy Act of 1969.

11. Before Defendants may commence distributing B-Vex Suspension, Ben-Tann Suspension, D-Tann Suspension, D-Tann AT Suspension, D-Tann CT Suspension, D-Tann DM Suspension, D-Tann HC Suspension, Dur-Tann DM Suspension, Duratan DM Suspension, L-All 12 Suspension, Nazarin Liquid, and Nazarin HC Liquid, and any product containing the same or similar ingredients as the drugs identified above, or any other new drug, Defendants shall first notify FDA in writing of their intention to do so, and shall also do the following:

A. For any product not covered by, and marketed in strict conformity to, an FDA OTC monograph, Defendants shall demonstrate to FDA that the drug is the subject of an approved application under 21 U.S.C. § 355, or is the subject of an investigational new drug application under 21 U.S.C. § 355(i). Defendants shall not commence distributing the product prior to receiving written notification from FDA that the product appears to be in compliance with this subparagraph. In no circumstance may FDA's silence be construed as a substitute for written notification.

B. If the product purports to be an OTC monograph drug, Defendants may not distribute such drug unless and until:

1. Defendants retain, at Defendants' expense, an independent person or persons (the "drug monograph expert"), who is without any personal or financial ties (other than the agreement) to Defendants and their families, and who, by reason of background, training, education, or experience, is qualified to review the labeling of Defendants' OTC drug(s) to determine whether such product complies with the applicable OTC drug monograph and other labeling requirements of the Act and FDA regulations. Defendants shall notify FDA in writing of the identity and qualifications of the drug monograph expert prior to his or her retention;

2. The drug monograph expert performs a comprehensive review of the OTC drug's formula and proposed labeling to determine whether the product strictly conforms to an applicable FDA OTC monograph and all labeling requirements, including 21 C.F.R. Part 201, and that the OTC drug is not otherwise misbranded;

3. The drug monograph expert certifies in writing to FDA that: (1) he or she has reviewed the OTC drug and its formula and labeling; (2) the OTC drug's formula and labeling conform to the requirements of an OTC drug monograph and all applicable labeling requirements, including 21 C.F.R. Part 201; and (3) the OTC drug is not otherwise misbranded. As part of this certification, the drug monograph expert shall include a full and complete detailed report of the results of his or her formula and labeling review, including references to the OTC monograph and labeling regulations addressed in the process of conducting the labeling review;

4. Defendants have provided to FDA any additional information requested by FDA after FDA's review of the drug monograph expert's certification pursuant to subparagraph 11(B)(3); and

5. FDA notifies Defendants in writing that Defendants appear to be in compliance with the requirements set forth in subparagraphs 11(B)(1) through (4). FDA will

notify Defendants as to whether Defendants appear to be in compliance within sixty (60) calendar days of the later of FDA's receipt of the drug monograph expert's certification as set forth in subparagraph 11(B)(3) or any information requested by FDA pursuant to subparagraph 11(B)(4). In no circumstance may FDA's silence be construed as a substitute for written notification.

12. After Defendants have complied with paragraphs 8(A) through (G) and FDA has notified them pursuant to paragraph 8(H), Defendants shall retain an independent person or persons who shall meet the criteria described in paragraph 8(B) ("auditor") to conduct audit inspections of their drug manufacturing operations not less than once every six (6) months for a period of two (2) years, and not less than once every twelve (12) months for a period of three (3) years thereafter. If Defendants so choose, the auditor may be the same person or persons retained as the CGMP expert in paragraph 8(B).

A. At the conclusion of each audit inspection, the auditor shall prepare a written audit report ("audit report") analyzing whether Defendants are in compliance with CGMP and identifying any deviations from CGMP ("audit report observations"). As a part of every audit report, except the first audit report, the auditor shall assess the adequacy of corrective actions taken by Defendants to correct all previous audit report observations. The audit reports shall be delivered contemporaneously to Defendants and FDA by courier service or overnight delivery service, no later than fifteen (15) business days after the date the audit inspections are completed. In addition, Defendants shall maintain the audit reports in separate files at their facility and shall promptly make the audit reports available to FDA upon request.

B. If an audit report contains any audit report observations indicating that Defendants are not in compliance with CGMP, Defendants shall, within thirty (30) calendar days

of receipt of the audit report, correct those observations, unless FDA notifies Defendants that a shorter time period is necessary. If, after receiving the audit report, Defendants believe that correction of the deviations will take longer than thirty (30) calendar days, Defendants shall, within ten (10) calendar days of receipt of the audit report, submit to FDA in writing a proposed schedule for completing corrections ("correction schedule"). The correction schedule must be reviewed and approved by FDA in writing prior to implementation by Defendants. In no circumstance will FDA's silence be construed as a substitute for written approval. Defendants shall complete all corrections according to the approved correction schedule. Within thirty (30) calendar days of Defendants' receipt of an audit report, unless FDA notifies Defendants that a shorter time period is necessary, or within the time period provided in a correction schedule approved by FDA, the auditor shall review the actions taken by Defendants to correct the audit report observations. Within five (5) business days of beginning that review, the auditor shall report in writing to FDA whether each of the audit report observations has been corrected and, if not, which audit report observations remain uncorrected.

13. A. If, at any time after entry of this Decree, FDA determines, based on the results of an inspection, the analysis of a sample, a report or data prepared or submitted by Defendants, the CGMP expert, the drug monograph expert, the auditor, or any other information, that Defendants have failed to comply with any provision of this Decree, have violated CGMP, the Act, or its implementing regulation, or that additional corrective actions are necessary to achieve compliance with this Decree, CGMP, the Act, or its implementing regulations, FDA may, as and when it deems necessary, notify Defendants in writing of the noncompliance and order Defendants to take appropriate corrective action, including, but not limited to, ordering Defendants to immediately take one or more of the following actions:

1. Cease all manufacturing, processing, packing, labeling, holding, and/or distributing any or all drug(s);
2. Recall, at Defendants' own expense, any drug that is adulterated, misbranded, unapproved, or otherwise in violation of this Decree, CGMP, the Act, or its implementing regulations;
3. Revise, modify, or expand any report(s) or plan(s) prepared pursuant to this Decree;
4. Submit additional reports or information to FDA;
5. Issue a safety alert; and/or
6. Take any other corrective actions as FDA, in its discretion, deems necessary to protect the public health or to bring Defendants into compliance with this Decree, CGMP, the Act, or its implementing regulations.

B. Unless a different time frame is specified by FDA in its order, within five (5) business days after receiving an order pursuant to subparagraph A, Defendants shall notify FDA in writing either that (1) Defendants are undertaking or have undertaken corrective action, in which event Defendants shall also describe the specific action taken or to be taken and the schedule for completing the action; or (2) Defendants do not agree with FDA's order. If Defendants notify FDA that they do not agree with FDA's order, Defendants shall explain in writing the basis for their disagreement; in so doing, Defendants may also propose specific alternative actions and specific time frames for achieving FDA's objectives.

C. If Defendants advise FDA in writing that they do not agree with FDA's order, FDA will review Defendants' notification and thereafter, in writing, affirm, modify, or withdraw its order, as the Agency deems appropriate.

D. If FDA affirms or modifies its order, Defendants shall, upon receipt of FDA's order, immediately implement the order (as modified, if applicable), and, if they so choose, bring the matter before this Court on an expedited basis. Defendants shall continue to implement diligently FDA's order, unless the Court issues an order to the contrary. Any matter brought before this Court shall be based exclusively on the record before FDA at the time the order in dispute was issued pursuant to subparagraph (C). No discovery shall be taken by either party.

14. Representatives of FDA shall be permitted, without prior notice and as and when FDA deems necessary, to make inspections of Defendants' place(s) of business and take any other measures necessary to monitor and ensure continuing compliance with the terms of this Decree. During such inspections, FDA representatives shall be permitted ready access to Defendants' place(s) of business including, but not limited to, all buildings, equipment, finished and unfinished materials and products, containers, labeling, and other promotional material therein; to take photographs and make video recordings; to take samples of Defendants' finished and unfinished materials and products, containers, labeling, and other promotional material; and to examine and copy all records relating to the manufacture, processing, packing, labeling, holding, and distribution of any and all of Defendants' drugs, including components, in order to ensure continuing compliance with the terms of this Decree. The inspections shall be permitted upon presentation of a copy of this Decree and appropriate credentials. The inspection authority granted by this Decree is separate from, and in addition to, the authority to make inspections under the Act, 21 U.S.C. § 374.

15. Defendants shall reimburse FDA for the costs of all FDA inspections, investigations, supervision, analyses, examinations, and reviews that FDA deems necessary to evaluate Defendants' compliance with any part of this Decree at the standard rates prevailing at the time

the activities are accomplished. As of the date of entry of this Decree, these rates are: \$81.61 per hour or fraction thereof per representative for inspection and investigative work; \$97.81 per hour or fraction thereof per representative for laboratory and analytical work; \$0.505 per mile for travel expenses by automobile, government rate or the equivalent for travel by air; and the published government per diem rate for subsistence expenses where necessary. In the event that the standard rates applicable to FDA supervision of court-ordered compliance are modified, these rates shall be increased or decreased without further order of the Court.

16. Within ten (10) calendar days of the entry of this Decree, Defendants shall post a copy of this Decree on a bulletin board in a common area at 10150 Old Columbia Road, Columbia, Maryland, and at any other location at which Defendants conduct business, and shall ensure that the Decree remains posted for a period of twelve (12) months at each location.

17. Within ten (10) calendar days of the date of entry of this Decree, Defendants shall provide a copy of the Decree, by personal service or certified mail (restricted delivery, return receipt requested), to each and all of their directors, officers, agents, employees, representatives, successors, assigns, attorneys, customers, and any and all persons in active concert or participation with any of them (collectively referred to as "Associated Persons"). Within thirty (30) calendar days of the date of entry of this Decree, Defendants shall provide to FDA an affidavit stating the fact and manner of their compliance with this paragraph, identifying the names, addresses, and positions of all persons who received a copy of this Decree pursuant to this paragraph.

18. In the event that any of the Defendants becomes associated with any additional Associated Person(s) at any time after entry of this Decree, Defendants immediately shall provide a copy of this Decree, by personal service or certified mail (restricted delivery, return receipt

requested), to such Associated Person(s). Within thirty (30) calendar days of each time any of the Defendants becomes associated with any such additional Associated Person, Defendants shall provide to the District Director, FDA Baltimore District Office, an affidavit stating the fact and manner of their compliance with this paragraph, identifying the names, addresses, and positions of all Associated Persons who received a copy of this Decree pursuant to this paragraph, and attaching a copy of the executed certified mail return receipts. Within ten (10) calendar days of receiving a request from FDA for any information or documentation that FDA deems necessary to evaluate Defendants' compliance with this paragraph, Defendants shall provide such information or documentation to FDA.

19. Defendants shall notify the District Director, FDA Baltimore District Office, in writing at least fifteen (15) calendar days before any change in ownership, character, or name of any of their businesses, including incorporation, reorganization, bankruptcy, assignment, sale resulting in the emergence of a successor business or corporation, or any other change in the structure or identity of SLI, or the sale or assignment of any business assets, such as buildings, equipment, or inventory, that may affect obligations arising out of this Decree. Defendants shall provide a copy of this Decree to any prospective successor or assign at least ten (10) calendar days prior to any sale or assignment. Defendants shall furnish FDA with an affidavit of compliance with this paragraph no later than ten (10) calendar days prior to such assignment or change in ownership.

20. If Defendants fail to comply with any of the provisions of this Decree, including any time frame imposed by this Decree, then, on motion of the United States in this proceeding, Defendants shall pay to the United States of America: five thousand dollars (\$5,000) in liquidated damages for each day such violation continues; and an additional sum of five thousand dollars

(\$5,000) in liquidated damages for each violation of the Act, its implementing regulations, and/or this Decree. The amount of liquidated damages in this paragraph shall not exceed one million dollars (\$1,000,000) per calendar year. The remedy in this paragraph shall be in addition to any other remedies available to the United States under this Decree or the law.

21. Defendants shall abide by the decisions of FDA, and FDA's decisions shall be final. All decisions conferred upon FDA in this Decree shall be vested in FDA's discretion and, if contested, shall be reviewed by this Court under the arbitrary and capricious standard set forth in 5 U.S.C. § 706(2)(A). Review by the Court of any FDA decision rendered pursuant to this Decree shall be based exclusively on the written record before FDA at the time the decision was made. No discovery shall be taken by either party.

22. Should the United States of America bring, and prevail in, a contempt action to enforce the terms of the Decree, Defendants agree to pay all attorneys' fees, travel expenses incurred by attorneys and witnesses, court costs, expert witness fees, and investigational and analytical expenses incurred in bringing such an action.

23. All notifications, correspondence, and communications to FDA required by the terms of this Decree shall be addressed to the District Director, FDA Baltimore District Office, 6000 Metro Drive, Suite 101, Baltimore, Maryland 21215.

24. If Defendants petition the Court for relief from this Decree and, at the time of the petition, in FDA's judgment, Defendants have maintained a state of continuous compliance with the Act, its implementing regulations, and this Decree for the sixty (60) months preceding the petition, Plaintiff will not oppose such petition.

25. This Court retains jurisdiction over this action and the parties thereto for the purpose of enforcing and modifying this Decree and for the purpose of granting such additional relief as

may be necessary or appropriate.

SO ORDERED, this 24 day of May, 2008



UNITED STATES DISTRICT JUDGE

The undersigned hereby consent to the entry of the foregoing Decree.


For Defendants



RAJESHWARI PATEL
Individually and on behalf
of Scientific Laboratories, Inc.,
as its President



AMIT ROY
Individually and on behalf
of Scientific Laboratories, Inc.,
as its Chief Executive Officer



PHILIP KATZ
Hogan & Hartson LLP
555 Thirteenth Street, N.W.
Washington, D.C. 20004
(202) 637-5632
Attorney for Defendants

For Plaintiff

ROD J. ROSENSTEIN
United States Attorney



ALLEN LOUCKS
Civil Chief
Assistant United States Attorney



GERALD C. KELL
Senior Trial Counsel
Office of Consumer Litigation
U.S. Department of Justice
Washington, D.C. 20044
(202) 514-1586

OF COUNSEL:

JAMES C. STANSEL
Acting General Counsel

GERALD F. MASOUDI
Chief Counsel
Food and Drug Division

ERIC M. BLUMBERG
Deputy Chief Counsel for Litigation

JASON W. SAPSIN
Associate Chief Counsel for Enforcement
United States Department of
Health and Human Services
Office of the General Counsel
5600 Fishers Lane, GCF-1
Rockville, MD 20857
(301) 827-1114